Predict your next investment

Venture Capital
FINANCE | Investment Firms & Funds
nextechinvest.com

See what CB Insights has to offer

Investments

66

Portfolio Exits

25

Funds

8

Service Providers

1

About Nextech Invest

Nextech Invest is a global investment manager founded 1998 and located in Zurich, Switzerland. With its unique oncology-focused funds, Nextech Invest is a dedicated investor in leading oncology companies developing cancer drugs and diagnostics. Nextech Invest benefits from the support of an active and committed Scientific Advisory Board of highly influential oncology advisors, chaired by David Livingston, MD, deputy director at the Dana-Farber Cancer Institute/Harvard Cancer Center.

Nextech Invest Headquarter Location

Scheuchzerstrasse 35

Zurich, CH-8006,

Switzerland

+41 (0)44 366 66 11

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Nextech Invest Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Nextech Invest Rank

Latest Nextech Invest News

IDRx Raises $122M in Series A Financing

Aug 2, 2022

IDRx, Inc. , a Plymouth, MA-based clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision combination therapies, raised $122m in Series A financing. The round was led by Andreessen Horowitz and Casdin Capital, with participation from Nextech Invest, Forge Life Science Partners and other undisclosed investors. Led by Ben Auspitz, co-founder and CEO, IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies. Its pipeline programs include small molecule tyrosine kinase inhibitors, IDRX-42 and IDRX-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRX-42 and IDRX-73 were acquired through license agreements with Merck KGaA, Darmstadt, Germany, and Blueprint Medicines, respectively. A Phase 1 first-in-human study of IDRX-42 has been initiated, and IDRX-73 is currently advancing towards the clinic. IDRX-42 was also recently granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of GIST. FinSMEs

Nextech Invest Investments

66 Investments

Nextech Invest has made 66 investments. Their latest investment was in IDRx as part of their Series A on August 8, 2022.

CBI Logo

Nextech Invest Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/2/2022

Series A

IDRx

$122M

Yes

3

5/10/2022

Series B

MOMA Therapeutics

$150M

No

7

1/14/2022

Series A

Alterome Therapeutics

$64M

Yes

6

1/6/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

10/5/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/2/2022

5/10/2022

1/14/2022

1/6/2022

10/5/2021

Round

Series A

Series B

Series A

Series A

Series B

Company

IDRx

MOMA Therapeutics

Alterome Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$122M

$150M

$64M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

7

6

10

10

Nextech Invest Portfolio Exits

25 Portfolio Exits

Nextech Invest has 25 portfolio exits. Their latest portfolio exit was Tyra Biosciences on September 15, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/15/2021

IPO

$99M

Public

8

8/6/2021

Acq - Pending

$99M

15

8/5/2021

Acquired

$99M

13

1/8/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

12/4/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/15/2021

8/6/2021

8/5/2021

1/8/2021

12/4/2020

Exit

IPO

Acq - Pending

Acquired

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

8

15

13

10

10

Nextech Invest Fund History

8 Fund Histories

Nextech Invest has 8 funds, including Nextech V Oncology.

Closing Date

Fund

Fund Type

Status

Amount

Sources

9/20/2017

Nextech V Oncology

Multi-Stage Venture Capital

Closed

$47M

1

7/20/2016

Oncology IV

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2011

Nextech III Oncology LP

Subscribe to see more

Subscribe to see more

$99M

10

9/30/2008

Nextech Venture II LP

Subscribe to see more

Subscribe to see more

$99M

10

5/27/2008

ONC Partners LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

9/20/2017

7/20/2016

12/31/2011

9/30/2008

5/27/2008

Fund

Nextech V Oncology

Oncology IV

Nextech III Oncology LP

Nextech Venture II LP

ONC Partners LP

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$47M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

Nextech Invest Service Providers

1 Service Provider

Nextech Invest has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Nextech Invest Team

7 Team Members

Nextech Invest has 7 team members, including current Managing Partner, Jakob Loven.

Name

Work History

Title

Status

Alfred Scheidegger

>>venture>>, ETH Zurich, and CSCS

Founder

Current

Jakob Loven

Third Rock Ventures, AstraZeneca, and Swedish Armed Forces

Managing Partner

Current

Rudolf Gygax

Managing Partner

Former

Felix Hofstetter

Managing Partner

Former

Myoung-Ok Kwon

Managing Partner

Former

Name

Alfred Scheidegger

Jakob Loven

Rudolf Gygax

Felix Hofstetter

Myoung-Ok Kwon

Work History

>>venture>>, ETH Zurich, and CSCS

Third Rock Ventures, AstraZeneca, and Swedish Armed Forces

Title

Founder

Managing Partner

Managing Partner

Managing Partner

Managing Partner

Status

Current

Current

Former

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.